The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R05 | Cough and cold preparations | |
| 3 | R05C | Expectorants, excl. combinations with cough suppressants | |
| 4 | R05CB | Mucolytics | |
| 5 | R05CB06 | Ambroxol |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.12 g |
| Active Ingredient | Description | |
|---|---|---|
| Ambroxol |
Ambroxol induces activation of the surfactant system by acting directly on the type II pneumocytes of the alveoles and the Clara cells in the region of the small airways. It promotes the formation and outward transfer of surface-active material in the alveolar and bronchial region of the foetal and adult lungs. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| FLUIBRON Syrup | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| MEDOVENT Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| MUCOBROXOL Syrup | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
